VWF/FVIII Treatment for von Willebrand Disease

wilate® – Balanced 1:1 formulation of VWF/FVIII developed specifically for VWD

wilate is a von Willebrand Factor/Factor VIII Complex indicated for use in children and adults with von Willebrand Disease (VWD) for on-demand treatment and control of bleeding episodes and for the perioperative management of bleeding.1 Unlike some VWF/FVIII products that were initially developed for the treatment of hemophilia A, wilate is the only VWF/FVIII complex developed specifically for the treatment of VWD.1-3

C91EE5D4-E447-4B1A-B74F-AA3551C13C59 Created with sketchtool.
A balanced 1:1 formulation of VWF/FVIII1,3,4

wilate contains a physiologic 1:1 ratio of VWF and FVIII to restore balance in both primary and secondary hemostasis

3b3ca2901560bf2e874aadfef9b26cbb Created with Sketch.
Effective control of major and minor bleeding4

In prospective clinical trials with 44 VWD patients and 1095 bleeding episodes, wilate resolved bleeds with a mean daily dose of 29 IU/kg

EA28AF2F-4ECA-4FBB-A474-E070E3BE9027 Created with sketchtool.
Low Recommended Loading and Maintenance Dosing* For All VWD Types1

Low dosing for the treatment of minor and major hemorrhages.

E1CC6DF5-4152-4135-89DF-254A166BBE62 Created with sketchtool.
Safety and Tolerability

No reported cases of thrombotic events in clinical trials with 92 VWD patients receiving 5676 infusions of wilate*

When using a FVIII-containing VWF product, the treating physician should be aware that continued treatment may cause excessive rise in FVIII activity. Monitor plasma levels of VWF:RCo and FVIII activities in patients receiving wilate to avoid sustained excessive VWF and FVIII activity levels, which may increase the risk of thrombotic events.
cta circles background
icon-clip-board Created with Sketch.

Learn more about the importance of why VWF and FVIII are important in maintaining hemostasis

Learn More
  1. wilate Full Prescribing Information. Paramus, NJ: Octapharma; rev September 2019.
  2. Kessler CM, et al. Thromb Haemost. 2011;106:279-288.
  3. Stadler M, et al. Biologicals. 2006;34:281-288.
  4. Berntorp E, et al. Haemophilia. 2009;15:122-130.
  5. Data on file. Paramus, NJ: Octapharma USA Inc; 2018.